NASDAQ:ADIL
Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. reported net income of −$8.0M in fiscal 2025. The diluted share count rose 244.5%.Summary generated from Adial Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−170.7%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+244.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −19 | −11 | −7 | −8 | −8 |
| Net income | −19 | −13 | −5 | −13 | −8 |
| Free cash flow | −12 | n/a | n/a | n/a | n/a |
Recent filings
- 8-KOther events
Oct 2, 2026 - 4Insider transaction report
Sep 21, 2026 - 8-KDirector or officer change
Sep 18, 2026 - 8-KEntry into a material agreement
Sep 16, 2026 - 8-KCurrent report
Aug 25, 2026 - DEF 14AProxy statement
Aug 24, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 21, 2026 - 8-KResults of operations and financial condition
Aug 17, 2026